Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Publication of CR10004ApublicationCriticalpatent/CR10004A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se proporcionan agonistas del receptor del neuropéptido-2 de fórmula (I), así como las sales farmacéuticamente aceptables, derivados y fragmentos del mismo, en el que los sustituyentes son tal y como se describen en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades como, por ejemplo, la obesidad y la diabetes.Neuropeptide-2 receptor agonists of formula (I) are provided, as well as pharmaceutically acceptable salts, derivatives and fragments thereof, in which the substituents are as described in the specification. These compounds, and the pharmaceutical compositions that contain them, are useful for the treatment of diseases such as obesity and diabetes.
Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
Compounds derived from carboxycyclopropyl- (bis-phenyl-oxamides); pharmaceutical composition containing them; process for the preparation of the compositions and the use of the compounds in the treatment of diabetes and cancer disorders among other diseases.
COMPOUNDS DERIVED FROM PIRROLOPIRIMIDINA, INHIBITORS OF CIANASA JAK3; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF REPLACEMENT OF TRANSPLANTS, AUTOIMMUN DISEASES
Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
Compounds derived from 4-imidazol-pyrimidin-2-amine, cdk2 kinase inhibitors; process for preparing the compounds; pharmaceutical composition comprising a compound; and use of the compounds in the preparation of medicaments for anti-cell proliferation, such as cancer, psoriasis, rheumatoid arthritis, among others.